The influence of HER2 genotypes as molecular markers on breast cancer outcome

DNA and Cell Biology

Volumn 27, Issue 10, 2008, Pages 575-579

  Mutluhan, Hicran ^a   Akbas, Etem ^a   Erdogan, Nazan Eras ^a   Soylemez, Fatma ^a   Senli, Mehmet Siddik ^a   Polat, Ayse ^a   Helvaci, Ilter ^a   Seyrek, Ertugrul ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; ISOLEUCINE; MOLECULAR MARKER; VALINE;

ADULT; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOME ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TURKEY (REPUBLIC);

ADULT; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2;

EID: 52749094794     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2007.0702     Document Type: Article

References (39)

1. Akisik, E., and Dalay, N. (2004). Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76, 260-263.
2. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., and Yamamoto, T. (1986). The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232, 1644-1646.
3. Ameyaw, M.M., Tayeb, M., Thornton, N., Folayan, G., Tariq, M., Mobarek, A., Evans, D.A.P., Ofori, A.D., and McLeod, H.L. (2002). Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 47, 172-175.
4. An, H.J., Kim, N.K., Oh, D., Kim, S.H., Park, M.J., Jung, M.Y., Kang, H., Kim, S.G., Lee, K.P., and Lee, K.S. (2005). HER2 genotype and breast cancer progression in Korean women. Pathol Int 55, 48-52.
5. Bargmann, C.I., Hung, M.C., and Weinberg, R.A. (1986). Multiple independent activations of neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657.
6. Baxter, S.W., and Campbell, I.G. (2001). Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93, 557-558.
7. Benusiglio, P.R., Lesueur, F., Luccarini, C., Conroy, D.M., Shah, M., Easton, D.F., Day, N.E., Dunning, A.M., Pharoah, P.D., and Ponder, B.A.J. (2005). Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7, 204-209.
8. Boring, C.C., Squires, T.S., Tong, T., and Montgomery, S. (1994). Cancer statistics, 1994. CA Cancer J Clin 44, 7-26.
9. Cooke, T., Reeves, J., Lanigan, A., and Stanton, P. (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12, S23-S28.
10. Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139.
11. Cox, D.G., Hankinson, S.E., and Hunter, D.J. (2005). The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 15, 447-450.
12. Goel, S., Mani, S., and Perez-Soler, R. (2002). Tyrosine kinase inhibitors: a clinical perspective. Curr Oncol Rep 4, 9-19.
13. Gullick, W.J. (2001). Update on HER-2 as a target for cancer therapy; alternative strategies for targeting the epidermal growth factor system in cancer (Review). Breast Cancer Res 3, 390-394.
14. Hauptmann, M., Sigurdson, A.J., Chatterjee, N., Rutter, J.L., Hill, D.A., Doody, M.M., and Struewing, J.P. (2003). Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 95, 1251-1252.
15. Hishida, A., Hamajima, N., Iwata, H., Matsuo, K., Hirose, K., Emi, N., and Tajima, K. (2002). Re: Population-based, case-control study of HER2 genetic polymorphisms and breast cancer risk. J Natl Cancer Inst 94, 1807-1808.
16. Hynes, N.E. (2000). Tyrosine kinase signalling in breast cancer (commentary). Breast Cancer Res 2, 154-157.
17. Kalami-Sarvestani, E., Talei, A.R., and Merat, A. (2004). Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215, 83-87.
18. Kalemi, T.G., Lambropoulos, A.F., Gueorguiev, M., Chrisafi, S., Papazisis, K.T., and Kotsis, A. (2005). The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222, 57-65.
19. Keshava, C., McCanlies, E.C., Keshava, N., Wolff, M.S., and Weston, A. (2001). Distribution of HER2 V655 genotypes in breast cancer cases and controls in the United States. Cancer Lett 173, 37-41.
20. Kim, Y.T., Kim, J.W., and Lee, J.W. (1998). C-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. Cancer Lett 132, 91-97.
21. Millikan, R., Eaton, A., Worley, K., Biscocho, L., Hodgson, E., Huang, W.Y., Geradts, J., Iacocca, M., Cowan, D., Conway, K., and Dressler, L. (2003). HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79, 355-364.
22. Montgomery, K., Gertig, D., Baxter, S., Milne, R., Dite, G., Mc-Credie, M., Giles, G., Southey, M., Hopper, J., and Campbell, I. (2003). The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidem Biomar 12, 1109-1111.
23. Nelson, E.N., Gould, M.N., Hampton, J.M., and Dietz, A.M. (2005). A case-control study of the HER2 ile655val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7, 357-364.
24. Olayioye, M.A. (2001). Update on HER2 as a target for cancer therapy; intracellular signalling pathways of ErbB2/HER-2 and family members (Review). Breast Cancer Res 3, 385-389.
25. Papewalis, J., Nikitin, A.Yu., and Rajewsky, M.F. (1991). G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19, 5452.
26. Pinkas-Kramarski, R., Eilam, R., Alroy, I., Levkowitz, G., Lonai, P., and Yarden, Y. (1997). Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 15, 2803-2815.
27. Pinto, D., Vasconcelos, A., Costa, S., Pereira, D., Rodrigues, H., Lopes, C., and Medeiros, R. (2004). HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13, 177-181.
28. Puputti, M., Sihto, H., Isola, J., Butzow, R., Joensuu, H., and Nupponen, N.N. (2006). Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet Cytogen 167, 32-38.
29. Rebbeck, T.R. (1999). Inherited genetic predisposition in breast cancer: a population-based perspective. Cancer 86, 2493-2501.
30. Rèvillion, F., Bonneterre, J., and Peyrat, J.P. (1998). ERBB2 oncogene in human breast cancer and its clinical significance (Review). Eur J Cancer 34, 791-808.
31. Rogers, C.E., Loveday, R.L., Drew, P.J., and Greenman J. (2002). Molecular prognostic indicators in breast cancer. Eur J Surg Oncol 28, 467-478.
32. Rutter, J., Chatterjee, N., Wacholder, S., and Struewing, J. (2003). The HER2 I655V polymorphism and breast cancer risk in Ashenazim. Epidemiology 14, 694-700.
33. Stern, D.F. (2000). Tyrosine kinase signalling in breast cancer; erbB family receptor tyrosine kinases (Review). Breast Cancer Res 2, 176-183.
34. Tomassi, S., Fedele, V., Lacalamita, R., Crapolicchio, A., Perlino, E., Bellizzi, A., and Paradiso, A. (2004). Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 209, 215-222.
35. Tsuda, H., Akiyama, F., Terasaki, H., Hasegawa, T., Kurosumi, M., Mitsunobu, S., Yamamori, S., and Goi, S. (2001). Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression carcinoma. Cancer 92, 2965-2974.
36. Wang-Gohrke, S., and Claude, J.C. (2001). Re: Population-based case-control study of HER2 genetic polymorphisms and breast cancer risk [letter]. J Natl Cancer Inst 93, 1657-1658.
37. Xie, D., Shu, X.O., Deng, Z., Wen, W.Q., Creek, K.E., Dai, Q., Gao, Y.T., Jin, F., Zheng, W. (2000). Population-based case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92, 412-417.
38. Yarden, Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2), 1-13.
39. Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137.